BIO vs BRTX · rev $2.58B vs rev $401.0K
BIO (BIO) versus BioRestorative Therapies Inc (BRTX) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
BioRestorative Therapies Inc (BRTX) is a biotechnology company listed on NASDAQ.
Latest reported BIO revenue for 2025-12-31 was $2.58B. Net income was $759.9M. Revenue was up 0.7% from 2024-12-31 to 2025-12-31. BIO currently screens at market cap $0.
Latest reported BRTX revenue for 2024-12-31 was $401.0K. Net income was -$9.0M. Revenue was up 175.0% from 2023-12-31 to 2024-12-31. BRTX currently screens at market cap $10.2M.
BIO currently screens at market cap $0. BRTX currently screens at market cap $10.2M.
Not investment advice. Open the BIO and BRTX stock pages for the full models.
Not investment advice.